CNTF
Executive Summary
Phase II trial of Regeneron's ciliary neurotrophic factor in over 50 ALS patients did not show statistically significant difference from placebo at doses ranging from .5 mcg/kg to 30 mcg/kg subcutaneous injections three times a week, Regeneron reports in secondary offering prospectus. "Comparisons of rates of deterioration in muscle strength and pulmonary function between patients treated with 30 mcg/kg of CNTF and placebo ranged in significance level between p = .08 and p = .20 and were of the magnitude anticipated on the basis of studies in animal models of motor neuron degeneration, Regeneron said. Anti-CNTF antibodies were seen in all patients dosed at 3 mcg/kg or greater. Based on results of the trial, the company is conducting a 700-patient Phase III study of CNTF ("The Pink Sheet" April 12, T&G-12).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth